secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0000078003-25-000149
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q3 adj EPS $0.87 beat; raises FY adj EPS guidance to $3.00-$3.15; sues Novo Nordisk over Metsera
--------------------------------------------------------------------------------

- Q3 revenues $16.7B (-7% operational YoY); reported EPS $0.62, adj EPS $0.87.
- Raises FY2025 adj diluted EPS guidance to $3.00-$3.15 from $2.90-$3.10; reaffirms revenue $61-64B.
- Reached landmark agreement with U.S. government on drug pricing; sues Novo Nordisk for tortious interference over Metsera acquisition.
- Inclacumab fails Phase 3 THRIVE-131 in sickle cell disease; $1.35B IPR&D charge for 3SBio deal.
- Expects ~$7.2B net cost savings by 2027; no share repurchases planned; $7.3B dividends paid YTD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/0000078003-25-000149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-20251104.htm
  HTML page:      https://secwatch.observer/filing/0000078003-25-000149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer